跨膜4超家族作为胰腺癌的一个预后因素

Transmembrane 4 superfamily as a prognostic factor in pancreatic cancer.

作者信息

Sho M, Adachi M, Taki T, Hashida H, Konishi T, Huang C L, Ikeda N, Nakajima Y, Kanehiro H, Hisanaga M, Nakano H, Miyake M

机构信息

First Department of Surgery, Nara Medical University, Japan.

出版信息

Int J Cancer. 1998 Oct 23;79(5):509-16. doi: 10.1002/(sici)1097-0215(19981023)79:5<509::aid-ijc11>3.0.co;2-x.

DOI:10.1002/(sici)1097-0215(19981023)79:5<509::aid-ijc11>3.0.co;2-x

PMID:9761121

Abstract

Several members of the transmembrane 4 superfamily (TM4SF) have been reported to be related to tumor progression and metastasis. The aims of our study were to clarify the relationship between TM4SF and pancreatic cancer and to determine the prognostic significance of TM4SF in human pancreatic cancer. The mRNA levels for MRP-1/CD9, KAI1/CD82 and ME491/CD63, which belong to the TM4SF gene family, were evaluated in 40 resectable pancreatic adenocarcinomas using reverse transcriptase-PCR. MRP-1/CD9 gene expression was associated with lymph node status, and with pathological status. Moreover, MRP-1/CD9 expression was inversely associated with histo-pathological grading. KAI1/CD82 gene expression was inversely associated with tumor status. ME491/CD63 gene expression, however, was conserved in all pancreatic cancers. The overall survival rate for the 22 patients whose tumors had decreased MRP-1/CD9 gene expression was strikingly lower than that for the 18 patients with MRP-1/CD9-positive tumors. The overall survival rate of the 15 patients who were KAI1/CD82-positive was significantly higher than that of the 25 patients with decreased KAI1/CD82 gene expression. In a multivariate analysis using the Cox proportional hazards model, MRP-1/CD9 and KAI1/CD82 status was found to be the most significant.

摘要

据报道，跨膜4超家族（TM4SF）的几个成员与肿瘤进展和转移有关。我们研究的目的是阐明TM4SF与胰腺癌之间的关系，并确定TM4SF在人类胰腺癌中的预后意义。使用逆转录聚合酶链反应（RT-PCR）在40例可切除的胰腺腺癌中评估了属于TM4SF基因家族的MRP-1/CD9、KAI1/CD82和ME491/CD63的mRNA水平。MRP-1/CD9基因表达与淋巴结状态和病理状态相关。此外，MRP-1/CD9表达与组织病理学分级呈负相关。KAI1/CD82基因表达与肿瘤状态呈负相关。然而，ME491/CD63基因表达在所有胰腺癌中均保持不变。22例肿瘤MRP-1/CD9基因表达降低的患者的总生存率明显低于18例MRP-1/CD9阳性肿瘤患者。15例KAI1/CD82阳性患者的总生存率显著高于25例KAI1/CD82基因表达降低的患者。在使用Cox比例风险模型的多变量分析中，发现MRP-1/CD9和KAI1/CD82状态最为显著。